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Abstract: Chemotherapy often results in various side effects, which can negatively affect health. 
Neuroblastoma, one of the most common types of childhood cancer, is but one of the examples, where 
side effects of chemotherapeutic treatment lower the quality of patient’s life. Modern way how to fight 
that is to enclose cytotoxic drug into some nanocarrier and its targeting to receptors overexpressed 
in membranes of cancer cells. Apoferritin (Apo), a natural protein cage, is very suitable 
as a nanocarrier, as it has no toxicity, immune system does not react to it, and drug can easily be 
loaded into its cavity. We enclosed ellipticine, clinical tested anti-cancer drug, into Apo cavity 
(creating ApoElli). The percentage of encapsulation was 61% and size and transmission electron 
microscopy analysis showed the preserved Apo ~12 nm icosahedral structure after this encapsulation.
Then we modified Apo outer surface with in silico-modelled peptides with hNET affinity and tested 
its toxicity and hemolytic activity. ApoElli modified with anti-hNET peptides was able to internalize
into neuroblastoma cells and to deliver the drug. However, it proved to be safe for human RBC, unlike 
pure ellipticine, which caused observable hemolysis at the same concentration.
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INTRODUCTION
Neuroblastoma is the most common cancer among children; the average age of diagnosis is 17 
month (Davenport et al. 2012). This cancer is arising in adrenal medulla or paraspinal ganglia 
and affects development of sympathetic nervous system. Over 50% of tumours are present 
in abdomen, neck, chest or pelvis (Vo et al. 2014). It is well known for its wide variety of clinical 
behaviour depending on the site of primary tumour, presence or absence of metastatic disease sites etc.
(Park et al. 2010). Diagnosis is performed by INSS (International Neuroblastoma Staging System),
whose criteria were first formulated in 1986 (Brodeur et al. 1993). Initial tests include CT or MRI 
to evaluate primary tumour, localize it, and define its size and possible spreading. Pathological 
confirmation is performed from biopsy of tumour tissue or from neuroblastoma tumour cells in bone 
marrow sample (Park et al. 2010). Treatment methods include surgery, chemotherapy, radiotherapy 
and biotherapy, as well as observation with selected circumstances (Maris et al. 2007). Approved 
drugs for neuroblastoma are for example doxorubicin hydrochloride, vincristine sulphate, Clafen®,
Cytoxan® or CEM®. Side effects of chemotherapeutic drugs can be very serious; some of them might 
appear years after successful treatment, such as 65% of childhood patients treated with doxorubicin 
hydrochloride who suffer from its cardiotoxicity in adulthood (Hutchins et al. 2017).
One way how to protect organism against these side effects is to close these drugs into some 
nanocarrier. For this experiment, apoferritin (Apo) was selected. It is a regular, uniformly self-
assembling nano-sized protein cage with excellent biocompatibility and unique structure that allows 
encapsulation of small molecules into its inner core (Belletti et al. 2017). It has many positive 
878
November 8–9, 2017, Brno, Czech Republic 24
years
characteristics, the mechanism of drug loading can be based on passive penetration process through 
pores (Linder 2013) or active pH-dependent disassembly/reassembly protocol (Dostalova et al. 2017).
Apo has a long lifetime and has affinity for tumour cells, though it has the ability to bind at human 
TfR1 receptor, which is over-expressed in rapidly proliferating cells (Li et al. 2010).
Apo surface can be further modified (Blazkova et al. 2013) and so can be directed to different 
cell types which increases its specificity. In this paper, we modified Apo surface with gold 
nanoparticles and use them to further modify the surface with peptides with high affinity for human 
norepinephrine transporter (hNET). The affinity of various peptide sequences for this receptor was 
tested using homology modelling (Haddad et al. 2017), and two different peptides were chosen 
for in vitro studies. This modification allowed to increase the Apo specificity and allow transport 
into cells through norepinephrine transporter receptor overexpressed on the membranes 
of neuroblastoma cells (Haddad et al. 2017).
The ability to deliver drug molecules to neuroblastoma cells was tested using ellipticine (Elli). It
is an alkaloid that was first isolated from Ochrosia elliptica. Preclinical and clinical studies showed 
that ellipticine has ability to arrest growth of several cancer cell types (Poljakova et al. 2009), but has 
multiple toxic side effects, including hemotoxicity (Auclair 1987). The mechanism of action has not 
been precisely described , but it combines DNA damage by inhibition of topoisomerase II, generation 
of cytotoxic free radicals, regulation of Bcl-2 family protein, rescue of mutant p53 activity 
and initiation of mitochondrial apoptosis pathway (Kuo et al. 2005). However Elli is a possible 
mutagen (Stiborova et al. 2001) and has no specificity, so can also eliminate healthy cell. To protect 




All chemicals of ACS purity were obtained from Sigma-Aldrich (St. Louis, MO, USA), unless 
stated otherwise. The pH was measured using pH meter WTW inoLab (Weilheim, Germany).
Encapsulation of Elli into Apo and modification of its surface with hNET peptides
200 µl of 1 mg/ml Elli (dissolved in 150 : 1 1 M HCl) was added to 20 µl of 50 mg/ml horse 
spleen Apo and 100 µl of ACS water. The solution was mixed for 15 min. 0.66 µl of 1 M sodium 
hydroxide was added to increase the pH and encapsulate the Elli inside Apo (creating ApoElli). 
The solution was mixed for 15 min. To remove non-encapsulated Elli molecules, solution exchange 
was performed three times (6000 g and 4 °C for 15 min). 25 µl of 1.3 nm gold nanoparticles was 
added to the sample and the solution was mixed for 12 h, creating ApoElli+Au. To remove unbound 
gold nanoparticles, solution exchange was performed two times. Next, 2.8 µl of 1.25 mg/ml anti-
hNET peptide A (GASNGINAYLC, creating ApoElli+hNET pA) or anti-hNET peptide 
B (SLWERLAYGIC, creating ApoElli+hNET pB) was added to the sample. The sample was mixed 
for 1 h at 600 rpm and 45 °C. Solution exchange was performed two times to remove unbound peptide 
molecules. Samples were stored at 4 °C until used.
Characterization of nanocarrier
To evaluate Elli concentration in ApoElli and its encapsulation efficiency, absorbance 
at wavelength of 420 nm and fluorescence with excitation wavelength of 420 nm and emission 
wavelength of 450 nm were measured using Tecan Infinite 200 PRO (Tecan, Männendorf, 
Switzerland).
The average size of the nanocarrier was determined by quasielastic dynamic light scattering 
with Zetasizer Nano ZS instrument (Malvern Instruments Ltd., Worcestershire, UK). The nanocarrier 
was diluted with ACS water (1 : 200), placed into polystyrene latex cell and measured at a detector 
angle of 173°, wavelength of 633 nm and temperature of 25 °C with the refractive index of dispersive 
phase 1.45 and 1.333 for the dispersive environment. For each measurement, disposable cuvettes type 
ZEN0040, were used, containing 50 µl of sample. The equilibration time was 120 s.
The measurements were performed in hexaplicates.
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Visualization of the nanocarrier shape was performed using transmission electron microscopy 
(TEM) with negative staining technique. For this purpose, an organotungsten compound, Nano-W
(Nanoprobes, Yaphank, NY, USA) was utilized. 4 µl of samples was deposited onto 400-mesh cooper 
grids coated with a continuous carbon layer. Dried grids were imaged by TEM (Tecnai F20; FEI, 
Hillsboro, OR, USA).
Toxicity of peptides and nanocarrier
MTT toxicity test were performed with neuroblastoma cell lines NB4, and SH-SY5Y
to evaluate the cytotoxicity of anti-hNET peptides A and B (in concentration range of 0.98-1000 µM),
Elli, ApoElli, ApoElli+hNET pA and ApoElli+hNET pB (in Elli concentration range of 0.078-80 µM).
5000 cells in 50 µl of medium were seeded in each well of 96-well plate. The cells were incubated
at 37 °C for at least 8 h. 50 µl of samples diluted in culture medium was added to cells, with one well 
receiving only culture medium. The plates were incubated at 37 °C for 12 h, after which 10 µl
of 5 mg/ml of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) dissolved in PBS 
(pH 7.4; 0.137 M NaCl + 0.0027 M KCl + 0.0014 M KH2PO4 + 0.0043 M Na2HPO4), was added 
to every well. After further incubation at 37 °C for 3 h, the solution was removed and 100 µl
of dimethylsulfoxide was added to disrupt the cells and release purple formazan. Absorbance
of the samples at 570 nm was measured by Tecan Infinite 200 PRO.
Hemolytic assay was performed to evaluate hemotoxicity of Apo, Elli, ApoElli,
ApoElli+hNET pA and ApoElli+hNET pB). Fresh blood is centrifuged at 3000 rpm for 10 min. Blood 
plasma was removed and red blood cells (RBCs) were repeatedly washed by 150 mM sodium chloride 
and centrifuged at 3000 rpm for 10 min, until supernatant cleared from haemolytic RBCs. After that, 
the RBCs were diluted with PBS and 150 µl was mixed with 150 µl of various concentrations
(0.0468-0.375 mM) of the tested Elli nanoformulations. PBS was used as negative control and 0.1% 
Triton X-100 was used as positive control. All samples were incubated at 37 °C for 1 h
and centrifuged at 3000 rpm for 10 min. Absorbance of 50 µl supernatant at 540 nm was measured 
using Tecan Infinite 200 PRO. The percentage of hemolysis was calculated using formula:
                                     %hemolysis = [(At - Ac)/(A100% - Ac)] • 100                                   (1)
At stands for absorbance of supernatant from sample, Ac represents absorbance of supernatant 
from negative control and A100% stands for absorbance of supernatant from positive control.
RESULTS AND DISCUSSION
Table 1 Average size of the tested nanocarriers







Average Elli encapsulation efficiency into Apo was 61%, as evaluated by absorbance 
measurement. The average size of the nanoparticles was measured to further confirm 
the surface modifications (Table 1). While the average size of empty Apo is ~12 nm, encapsulation 
of Elli increased it to 15.7 nm. This could be caused by less rigid assembly after filling of the cavity 
or by drug molecules attached to the outer surface of the nanocarrier. Modification with anti-hNET 
peptide A increased the size to an average of 18.2 nm, proving that if there were drug molecules 
on the outer surface, their presence did not hamper binding of targeting peptides. The biggest 
size, around 43.8 nm, was measured for ApoElli modified with anti-hNET peptide B. Since during 
the homology modelling the peptide B was found to bind to other peptide B molecules, this was 
probably caused by formation of multiple ApoElli connected by these peptides. 
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Figure 1 TEM visualization, A –Apo; B – ApoElli; C – ApoElli +Au, arrow shows Au nanoparticles, D 
– ApoElli+hNET pA, arrows show visible peptide tails E – ApoElli+hNET pB, arrows show visible 
peptide tails
To evaluate the structure of nanoparticles, TEM visualization was used (Figure 1). The structure 
of unloaded Apo (Figure 1A) shows icosahedral cage with empty cavity. On the next picture is Apo 
loaded with Elli (Figure 1B, ApoElli) where a filled cavity can be clearly observed. Gold nanoparticles 
on ApoElli surface can be seen as a dark ring around ApoElli (arrow on Figure 1C, ApoElli+Au).
Peptides present on the surface of ApoElli+hNET pA and ApoElli+hNET pB were observed as small 
protein tails on the icosahedral cage (arrows on Figures 1D and 1E, respectively). However, all
pictures showed typical apoferritin structure in its stable and assembled state, proving that 
the performed surface modifications did not lead to disassembly of its structure.
Table 2 MTT toxicity test
Cell line Sample 24IC50 (µM)
SH-SY5Y anti-hNET peptide A 330.0



















To evaluate the cytotoxicity of these nanocarriers for neuroblastoma cells, MTT toxicity test 
was performed using two different neuroblastoma cell lines, SH-SY5Y and NB4. The peptides 
themselves proved non-toxic for these neuroblastoma cells lines, where their 24IC50 was 30 fold
higher than that used for ApoElli targeting. Empty Apo was did not show any toxicity. Samples 
containing Elli reached 24IC50 at low dosage, and encapsulated Elli reached 24IC50 with concentration 
2.5 fold higher than pure Elli. These results show that Apo nanocarrier was able to deliver Elli cargo 
to cells, where its structure was disassembled due to acidic endosomal environment and Elli was 
released. 
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Figure 2 Hemolysis test; Letter describe samples, A – Apo, B – Elli, C – ApoElli, D – ApoElli+hNET 
pA, E – ApoElli+hNET pB, graph shows percentage of hemolysis by highest concentration of samples
Hemolytic test was performed using fresh RBCs. 0.1% Triton was used as a positive control, 
as it hemolysed 100% of RBCs. PBS was used as a negative control. Empty Apo had no hemolytic
effect at all (Figure 2A). Pure Elli caused observable hemolysis, as it hemolysed 3.6% of RBCs at its 
highest concentration (Figure 2B). Elli encapsulated into Apo (Figure 2C) and its modifications 
with anti-hNET peptides A (Figure 2D) and B (Figure 2E) were not hemolytic for RBCs. Percentage 
of hemolysis caused by these nanoformulations was below 1% at all tested concentrations. It can be 
seen, that ApoElli with peptide B was a little less hemolytic then ApoElli and ApoElli with peptide A.
CONCLUSION 
We managed to create possible nanocarrier loaded with anti-cancer drug ellipticine. By closing 
Elli into this protein carrier Apo we can protect healthy cells as with modification of Apo surface we 
are able to specifically target it to cancer cells. In this paper we encapsulated Elli into Apo 
and modified its outer surface with gold nanoparticles and anti-hNET peptide A and hNET peptide B
for neuroblastoma targeting. We characterized the size and structure of these particles and proved that 
these modifications did not affect the structure of Apo and so its function. We also demonstrated 
safety of this nanocarrier by itself, but also when loaded with Elli and modified with targeting 
peptides. Elli itself proved toxic for both cancer and red blood cells, even in low concentration. 
Whereas the encapsulation in Apo keeping the toxicity for neuroblastoma cancer cells while 
eliminating the toxicity for red blood cells, although the highest concentration applied to red blood 
cells was almost 25 fold higher than that used on neuroblastoma cancer cells. By modifying of Apo
surface, we proved that the transport of cytotoxic drug with many side effects can be more specific 
to affect only target cancer cells. Still, further experiments are needed to evaluate the targeting 
and in vivo behaviour of this nanocarrier.
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